Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
(4) - EconoTimes)
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on September 27, 2017, the Compensation Committee of the Board of Directors approved, effective as of September 29, 2017, the grant of inducement stock options to purchase an aggregate of 82,000 shares of common stock to three new employees.
Each stock option shall have an exercise price per share of $54.03, the closing price per share of the Company’s Common Stock on September 29, 2017, and will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares vest ratably over the subsequent 36 months, subject to each new employee's continued service with the Company. Each stock option has a ten-year term and is subject to the terms and conditions of the Company's Inducement Plan and the stock option agreement pursuant to which the option was granted.
The stock options were granted as inducements material to the new employees entering into employment with Portola in accordance with NASDAQ Listing Rule 5635(c)(4).
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of its potentially life-saving therapies. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions.
Investor Contact:
Michele Mantynen
Portola Pharmaceuticals
[email protected]
Media Contact:
Patrick Ryan
W2O Group
[email protected]
